# Bulgaria Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Bulgaria HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Bulgaria (BGR)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $776.0M
- Products: 33
- Buyer markets: 28
- Average CAGR: +15.0%
- Global sector size: $685.9B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $639.4M | $115.8B | +31.6% | 22 | +0.4% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $150.4B | $20.3M | $58.9B | -2.0% | 13 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $29.0B | $3.8M | $24.0B | +25.8% | 7 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $454.2K | $16.2B | +18.5% | 7 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.6B | $442.1K | $13.4B | -6.6% | 5 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $26.8M | $11.7B | +20.8% | 2 | +0.2% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $12.6B | $54.2M | $10.7B | +24.3% | 4 | +0.5% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.3M | $10.7B | -0.8% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $13.7B | $7.1M | $10.4B | +30.1% | 6 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $3.3K | $8.5B | -16.4% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $4.5M | $7.0B | +20.6% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $2.0M | $6.3B | +53.0% | 3 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $38.0K | $6.2B | +6.4% | 2 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $114.7 | $4.9B | -39.9% | 1 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $12.1 | $4.8B | -34.7% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $891.4K | $4.1B | +16.4% | 2 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $45.7K | $3.8B | +85.1% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $5.2K | $3.3B | +13.6% | 2 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.6B | $14.7 | $3.1B | -13.7% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $92.7 | $2.4B | +7.3% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.3B | $20.0K | $2.3B | +95.8% | 1 | +12.2% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $392.1K | $2.1B | +26.6% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $13.6M | $2.0B | +38.6% | 1 | +0.4% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $1.3K | $2.0B | -25.6% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $611.4K | $1.9B | +47.7% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $123.8 | $1.8B | -29.3% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $604.3 | $1.8B | -66.4% | 1 | +0.0% |
| HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $40.5 | $1.5B | -40.3% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $12.9K | $1.4B | +0.9% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $722.2 | $1.4B | +10.3% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $21.2K | $1.2B | -7.8% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $30.4 | $1.1B | -48.5% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $113.2K | $1.1B | +16.5% | 1 | +0.3% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $90.1B calculated opportunity across 14 products.
- Switzerland, Liechtenstein (CHE): $36.5B calculated opportunity across 4 products.
- Germany (DEU): $36.1B calculated opportunity across 11 products.
- China (CHN): $25.5B calculated opportunity across 10 products.
- Belgium (BEL): $23.9B calculated opportunity across 5 products.
- Netherlands (NLD): $20.7B calculated opportunity across 6 products.
- Slovenia (SVN): $12.9B calculated opportunity across 2 products.
- United Kingdom (GBR): $12.2B calculated opportunity across 6 products.
- Italy (ITA): $12.1B calculated opportunity across 3 products.
- France (FRA): $10.4B calculated opportunity across 5 products.
- Spain (ESP): $10.1B calculated opportunity across 5 products.
- Canada (CAN): $7.9B calculated opportunity across 4 products.

## Growth stars

- HS 284190: +95.8% average CAGR, $2.3B calculated opportunity.
- HS 290110: +85.1% average CAGR, $3.8B calculated opportunity.
- HS 382200: +53.0% average CAGR, $6.3B calculated opportunity.
- HS 382319: +47.7% average CAGR, $1.9B calculated opportunity.
- HS 300420: +38.6% average CAGR, $2.0B calculated opportunity.
- HS 300490: +31.6% average CAGR, $115.8B calculated opportunity.
- HS 300439: +30.1% average CAGR, $10.4B calculated opportunity.
- HS 381512: +26.6% average CAGR, $2.1B calculated opportunity.
- HS 300220: +25.8% average CAGR, $24.0B calculated opportunity.
- HS 382600: +24.3% average CAGR, $10.7B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $115.8B calculated opportunity.
- HS 300215: 13 buyer markets, $58.9B calculated opportunity.
- HS 300220: 7 buyer markets, $24.0B calculated opportunity.
- HS 382499: 7 buyer markets, $16.2B calculated opportunity.
- HS 300439: 6 buyer markets, $10.4B calculated opportunity.
- HS 300212: 5 buyer markets, $13.4B calculated opportunity.
- HS 382600: 4 buyer markets, $10.7B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 293499: 3 buyer markets, $8.5B calculated opportunity.
- HS 330499: 3 buyer markets, $7.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.